San Francisco, United States
Verge Labs, founded in 2015 and headquartered in San Francisco, is a pioneering AI lab focused on revolutionizing drug discovery. Carrying the bold slogan, "Better drugs, faster. For patients who can’t wait," the company is strategically positioned at the intersection of biotechnology, health care, and machine learning.
Specializing in the creation of AI models based on proprietary multimodal human tissue data, Verge Labs accelerates research for treatments specifically in CNS diseases and other intricate human conditions. Verge's partnerships with pharmaceutical and biotech giants are essential to their strategy, which includes innovative solutions like target discovery, in-silico validation, and biomarker prediction.
Significant financial backing underscores its potential, with a $98.00M Series B investment closed on 01 December 2021, involving notable investors such as BlackRock, Tao Capital Partners, and Eli Lilly. This strong investor confidence speaks to the promising trajectory of Verge Labs.
